Olive Leaf Extracts in the Control of Hypertension

Last updated: November 5, 2024
Sponsor: University of Monastir
Overall Status: Active - Recruiting

Phase

2/3

Condition

Vascular Diseases

Williams Syndrome

Stress

Treatment

Placebo Atherolive

atherolive-drug

Clinical Study ID

NCT05636826
ATHEROLIVE-HTA
  • Ages 18-95
  • All Genders

Study Summary

This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital).

Patients over 18 years of age with:

Arterial hypertension (hypertension).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • patients over 18 years of age with:

Arterial hypertension (hypertension)

Exclusion

Exclusion Criteria:

  • . Exclusion criteria: None.

Study Design

Total Participants: 500
Treatment Group(s): 2
Primary Treatment: Placebo Atherolive
Phase: 2/3
Study Start date:
December 30, 2023
Estimated Completion Date:
December 30, 2025

Study Description

This study will be carried out in 2 emergency departments (at the exit of the emergency room, patients included in the GR2 study) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital).

All the population will benifit of a biological assessment which include:

Complete lipid profile, blood sugar, creatinine

one population will be randomized:

The population of patients with hypertension.

For patients in the hypertension group:

A blood pressure with holter will be carried out for 24 hours .

Connect with a study center

  • University Hospital Fattouma Bourguiba Monastir

    Monastir,
    Tunisia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.